Trial · NCT03574597
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit | Semaglutide | 97 | Participants | ||
| Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit | Placebo | 122 | Participants | ||
| Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%]) | Semaglutide | 306 | Participants | ||
| Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%]) | Placebo | 1059 | Participants | ||
| Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure | Semaglutide | 155 | Participants | ||
| Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure | Placebo | 198 | Participants | ||
| Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%]) | Semaglutide | 623 | Participants | ||
| Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%]) | Placebo | 1501 | Participants | ||
| Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%]) | Semaglutide | Week 52 | 3363 | Participants | |
| Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%]) | Placebo | Week 52 | 955 | Participants | |
| Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%]) | Semaglutide | Week 104 | 3271 | Participants | |
| Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%]) | Placebo | Week 104 | 978 | Participants | |
| Change in Systolic Blood Pressure (SBP) | Semaglutide | -3.8 | Standard Deviation 16.4 | Millimetre of mercury (mmHg) | |
| Change in Systolic Blood Pressure (SBP) | Placebo | -0.6 | Standard Deviation 16.0 | Millimetre of mercury (mmHg) | |
| Change in Diastolic Blood Pressure (DBP) | Semaglutide | -1.1 | Standard Deviation 10.4 | mmHg | |
| Change in Diastolic Blood Pressure (DBP) | Placebo | -0.4 | Standard Deviation 10.4 | mmHg | |
| Change in Pulse | Semaglutide | 3.8 | Standard Deviation 11.0 | beats per mintue (bpm) | |
| Change in Pulse | Placebo | 0.9 | Standard Deviation 10.7 | beats per mintue (bpm) | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline | Semaglutide | 0.61 | Geometric Coefficient of Variation 149.53 | ratio of hsCRP | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline | Placebo | 1.00 | Geometric Coefficient of Variation 133.25 | ratio of hsCRP |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03574597/results?page=2